Skip to main content

Table 1 Characteristics of 82 NPC patients with residual cervical lymphadenopathy

From: The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study

Characteristic Tumor cells in cervical lymph nodes [cases (%)] P value
Presence Absence
Total 68 14  
Sex    0.045
 Male 52 (76.5) 7 (50.0)  
 Female 16 (23.5) 7 (50.0)  
Pathological type    0.133&
 WHO type II 2 (2.9) 2 (14.3)  
 WHO type III 66 (97.1) 12 (85.7)  
T stagea    0.334#
 T1 0 (0) 1 (7.1)  
 T2 24 (35.3) 4 (28.6)  
 T3 35 (51.5) 7 (50.0)  
 T4 9 (13.2) 2 (14.3)  
N stagea    0.974#
 N1 13 (19.1) 3 (21.4)  
 N2 34 (50.0) 7 (50.0)  
 N3 21 (30.9) 4 (28.6)  
Clinical stagea    0.179
 II 7 (10.3) 4 (28.6)  
 III 34 (50.0) 5 (35.7)  
 IV 27 (39.7) 5 (35.7)  
EBV DNA before treatment (copies/mL) 0.252
 ≤ 4000 23 (33.8) 7 (50.0)  
 > 4000 45 (66.2) 7 (50.0)  
EBV DNA before surgery (copy/mL) < 0.001#
 0 32 (47.1) 14 (100)  
 > 0 36 (52.9) 0 (0.0)  
VCA-IgA    0.988
 < 1:320 29 (42.6) 6 (42.9)  
 ≥ 1:320 39 (57.4) 8 (57.1)  
EA-IgA    0.196
 < 1:20 27 (39.7) 3 (21.4)  
 ≥ 1:20 41 (60.3) 11 (78.6)  
Size of lymph node 0.747
 < 3 cm 42 (61.8) 8 (57.1)  
 ≥ 3 cm 26 (38.2) 6 (42.9)  
Lymph node invasion 1.000#
 Yes 4 (5.9) 0 (0.0)  
 No 64 (94.1) 14 (100)  
Lymph node necrosis 0.865
 Yes 16 (23.5) 3 (21.4)  
 No 52 (76.5) 11 (78.6)  
Treatment for cervical lymphadenopathy 0.285#
 Surgery alone 54 (79.4) 14 (100)  
 Surgery + chemotherapy 9 (13.2) 0 (0.0)  
 Surgery + radiotherapy 5 (7.5) 0 (0.0)  
Treatment for NPC    0.957#
 Radiotherapy alone 4 (5.9) 1 (7.15)  
 CCRT 22 (32.4) 5 (35.7)  
 NAC + CCRT 38 (55.9) 7 (50.0)  
 CCRT + AC 4 (5.9) 1 (7.15)  
Irradiation technique    1.000&
 2D-RT 7 (10.3) 1 (7.1)  
 IMRT 61 (89.7) 13 (92.9)  
  1. NPC nasopharyngeal carcinoma, WHO World Health Organization, EBV Epstein-Barr virus, VCA viral capsid antigen, IgA immunoglobulin A, EA early antigen, 2D-RT two-dimensional radiotherapy, IMRT intensity-modulated radiotherapy, CCRT concurrent chemoradiotherapy, NAC neoadjuvant chemotherapy, AC adjuvant chemotherapy
  2. P values were calculated with the Chi square test, &Continuity Correlation, and #the Fisher’s exact test, respectively
  3. aThe 7th edition of American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system was used
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us